Astrana Health, Inc.(ASTH)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #840 of 2,961 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ASTH Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Astrana Health, Inc. (ASTH), a Technology sector company. 13F Pro's AI-powered ranking engine scores ASTH at 60.7/100 on a 32-signal composite quality model, placing it at rank #840 of 2,961 stocks — the top half of the AI-ranked universe. ASTH scores in the top quartile across revenue growth (94.5), earnings quality (80.1). Areas of concern include free cash flow (34.0) and profitability (36.9), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Astrana Health, Inc. reports quarterly revenue of $972.5M, net income of $19.7M, an operating margin of 3.5%. Top institutional holders of ASTH by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ASTH trades on the Nasdaq exchange and files with the SEC under CIK 1083446. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ASTH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Astrana Health, Inc. directly from SEC EDGAR. Astrana Health, Inc.'s 13F Pro composite quality score has ranged between 58 and 63 since 2024, currently 60.7 — a stable long-term trajectory across 55 quarterly and live scoring snapshots.
Revenue
Q2 2026
$972.5M
Net Income
Q2 2026
$19.7M
Free Cash Flow
Q2 2026
$28.9M
Operating Margin
Q2 2026
3.5%
ROIC
Q2 2026
7.8%
D/E Ratio
Q2 2026
1.13
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+56.4% YoYNet Income
-47.9% YoYOperating Income
-12.1% YoYEPS (Diluted)
-48.9% YoYTotal Assets
+63.8% YoYTotal Debt
+139.0% YoYOp. Cash Flow
+119.5% YoYFree Cash Flow
+136.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $3.18B +56.4% | $2.03B +46.7% | $1.39B +21.2% | $1.14B +47.8% | $773.9M +12.6% | $687.2M |
| Net Income | $22.5M -47.9% | $43.1M -28.9% | $60.7M +34.4% | $45.2M -34.5% | $68.9M +82.9% | $37.7M |
| Operating Income | $78.5M -12.1% | $89.3M +5.6% | $84.6M -18.8% | $104.3M +6.2% | $98.2M +22.0% | $80.5M |
| EPS (Diluted) | $0.46 -48.9% | $0.90 +6616.4% | $0.01 +30.1% | $0.01 -34.8% | $0.02 +50.5% | $0.01 |
| Total Assets | $2.22B +63.8% | $1.35B +45.2% | $933.4M -3.4% | $966.2M +11.4% | $867.4M +6.1% | $817.5M |
| Total Debt | $1.04B +139.0% | $434.7M +56.1% | $278.4M +36.5% | $204.0M +11.1% | $183.7M -23.8% | $241.1M |
| Operating Cash Flow | $114.6M +119.5% | $52.2M -23.5% | $68.2M -16.9% | $82.1M +16.8% | $70.3M +52.4% | $46.2M |
| Free Cash Flow | $104.5M +136.6% | $44.2M +11.3% | $39.7M -32.9% | $59.2M +15.8% | $51.1M +13.6% | $45.0M |
Get alerted when ASTH's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Astrana Health, Inc. including:
Top Institutional Holders of ASTH
BlackRock, Inc.
$320.2M6,899,990 shVANGUARD PORTFOLIO MANAGEMENT LLC
$120.9M2,605,775 shVANGUARD CAPITAL MANAGEMENT LLC
$90.3M1,946,431 shSTATE STREET CORP
$80.7M1,738,930 sh325 CAPITAL LLC
$74.9M1,613,843 shDIMENSIONAL FUND ADVISORS LP
$68.1M1,468,508 shWELLINGTON MANAGEMENT GROUP LLP
$60.0M1,292,573 shGEODE CAPITAL MANAGEMENT, LLC
$54.2M1,167,974 shBANK OF AMERICA CORP /DE/
$39.5M852,145 shFMR LLC
$31.8M685,922 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $320.2M | 6,899,990 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $120.9M | 2,605,775 |
| VANGUARD CAPITAL MANAGEMENT LLC | $90.3M | 1,946,431 |
| STATE STREET CORP | $80.7M | 1,738,930 |
| 325 CAPITAL LLC | $74.9M | 1,613,843 |
| DIMENSIONAL FUND ADVISORS LP | $68.1M | 1,468,508 |
| WELLINGTON MANAGEMENT GROUP LLP | $60.0M | 1,292,573 |
| GEODE CAPITAL MANAGEMENT, LLC | $54.2M | 1,167,974 |
| BANK OF AMERICA CORP /DE/ | $39.5M | 852,145 |
| FMR LLC | $31.8M | 685,922 |
Companies Similar to ASTH
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
ADTRAN Holdings, Inc.
ICHOR HOLDINGS, LTD.
SANMINA CORP
VIAVI SOLUTIONS INC.
BENCHMARK ELECTRONICS INC
PC CONNECTION INC
Penguin Solutions, Inc.
LSI INDUSTRIES INC
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Technology Companies
View all Technology →Put ASTH on your watchlist
Track score changes the day Astrana Health, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ASTH a good stock to buy?
13F Pro's AI-powered analysis of Astrana Health, Inc. (ASTH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ASTH are available on the ASTH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ASTH is classified as a mid company.
Which hedge funds own ASTH?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ASTH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Astrana Health, Inc.'s investment landscape.